harryvanluik schreef op 5 juli 2016 15:59:
Ik hoor zo weinig over de zogezegde "eigen" marker die Kevin Conroy (Exact Sciences) wil laten ontwikkelen om de MDXH-marker er uit te smijten tegen 2018. Maar er is bovendien toch een overeenkomst waarbij Exact exclusieve rechten gekregen heeft in ruil voor bepaalde voorwaarden…Die voorwaarden houden o.a. in dat deze overeenkmst zou moeten lopen tot ergens in 2028.
lees zelf maar wat er stond geschreven:
In 2010, MDxHealth entered into an exclusive license agreement with Exact Sciences Corporation for stool-based screening of colorectal cancer. Under the terms of the agreement, Exact Sciences obtained exclusive, worldwide rights to use up to two of MDxHealth’s DNA methylation biomarkers in stool-based detection of colorectal cancer, as well as non-exclusive access to MDxHealth’s MSP platform technology for use with those biomarkers. With the launch of licensee Exact Sciences’ FDA-approved Cologuard test, MDxHealth expects to recognize a milestone fee and deferred license fees in excess of $0.5 million in the near term, and is eligible to receive minimum annual maintenance fees of $100,000 per year, sales milestones of $300,000 after Cologuard attains net sales of $10 million, $750,000 after Cologuard attains net sales of $50 million, and $1 million after Cologuard attains net sales of $50 million in a single calendar year, as well as running royalties in the mid-single digit range.
The license agreement is expected to remain in effect until the last of the licensed patents expires in 2028